Inimmune is a private clinical stage company dedicated to developing immuno-therapeutics. It is focused on advancing its Toll Like Receptor ligand portfolio as immunotherapeutics and vaccine adjuvants to be used alone or in combination to treat cancer, allergy, autoimmune disorders and infectious diseases. Our disruptive, disease modifying allergy therapy is making excellent progress in a phase I trial and our immuno- oncology therapy will begin phase I enrollment in January 2024. The company, through its chemistry, formulation and immunology expertise has been awarded over $40 million in NIH-sponsored programs with leading U.S. based universities developing vaccines to treat a variety of conditions including infectious diseases and opioid addiction. In addition to our allergy and oncology phase I clinical trials, we expect to initiate an additional three clinical trials in the next 18 months.